Free online course: learn how to be an effective Parkinson’s campaigner
Author: Parkinson's Life editorsPublished: 30 June 2016
Prep: Cook: Serves:
A new educational course gives people with Parkinson’s and their carers the tools to become better campaigners
The European Patient Ambassador Programme (EPAP) is a free online course for anyone affected by Parkinson’s disease and other chronic conditions. The course teaches patients and their carers the skills and knowledge they need to represent themselves successfully and become involved in advocacy. More than 500 patients have completed it so far.
Divided into seven modules, the programme features classes on how to access reliable information become involved in research and work with the media. There is a new module on participating in healthcare conferences with input from a specialist patient advisory group.
EPAP is open to patients facing all conditions, although they are an organisation specialising in respiratory conditions. The Dutch-language EPAP launched in Amsterdam at the European Respiratory Society (ERS) Congress in February and there are plans to translate EPAP into further European languages, with Italian and a French versions launching later in the year.
The EPAP website also contains further resources in additional languages and news on patient involvement.
What does it mean to be a Parkinson’s advocate?
Advocacy – or campaigning – is a way you can make the voice of people with Parkinson’s heard. It helps to increase the power and influence of your organisation. It could be a campaign raising awareness of the need for greater support for carers; or more Parkinson’s nurses; it could be lobbying for a certain drug or treatment to be fully reimbursed. Advocacy is about making a change for the people you represent.
Love creating art? Here’s your chance to help raise awareness on World PD Day
Enter this art competition to commemorate World Parkinson’s Day
7 days ago
Investigational Parkinson’s disease dementia therapy fails in clinical trial
Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase. This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study. The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function. Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did…
A new intimacy guide aims to support people with Parkinson’s disease in the US
Does sexual wellness in the Parkinson’s community need more focus? It’s an area that the American Parkinson Disease Association (APDA) and media brand Havas Health Plus have targeted through the launch of a free intimacy guide. Available to people in the US, ‘The ParkinSex Booklet & Kit’ aims to support those whose relationships may have been impacted by emotional and physical distance linked to the condition. Alongside an educational guide, the kit includes items such as candles, coupons for adaptative clothing and massage stones. Following a positive response to an initial pilot distribution of the guides in the US, there is now a waitlist for future kits. Commenting on the launch in a press release, APDA president and CEO Leslie Chambers said: “The challenges of Parkinson’s can often result in intimacy and connection getting left behind. This is why we created ‘The ParkinSex Booklet & Kit’, to help people with…
How prevalent are non-visual hallucinations in Parkinson’s disease?
Some people in the later stages of Parkinson’s can experience hallucinations – “when you see, hear or feel things that aren’t there”. With most research into this topic centred on visual hallucinations, a team in Australia set out to investigate data around non-visual hallucinations in people with the condition. Published in the ‘Journal of Neurology’, the analysis drew on 91 relevant studies released between 1970 and 2022. The team found that visual hallucinations appeared to be most common, with an expected prevalence of up to 96.6%. Meanwhile, non-visual hallucinations – including auditory (relating to the sense of hearing) and olfactory (relating to the sense of smell) – had an estimated prevalence of up to 73.3%. Concluding that non-visual hallucinations may “impact a notable proportion” of people with the condition, the team said: “More direct research and clinical attention need to be devoted to the study and management of such hallucinatory…